title: Photodynamic therapy for retinal capillary hemangioma.
abstract: OBJECTIVE
  To describe the results of photodynamic therapy (PDT) for juxtapapillary and peripheral retinal capillary hemangioma (RCH).
  
  
  METHODS
  Interventional case series of four eyes (four patients) with juxtapapillary RCH and one eye (one patient) with peripheral RCH. Two eyes with juxtapapillary RCH had received two sessions of full-fluence, double-duration PDT; whereas other two eyes had received single session of half-fluence, single-duration PDT. The peripheral RCH was treated with a single session of full-fluence, single-duration PDT.
  
  
  RESULTS
  Two patients had von Hippel-Lindau disease. Follow-up duration ranged from 4 months to 1 year. Pre-PDT visual acuity (VA) ranged from 20/200 to HM (juxtapapillary RCH) and 20/100 (peripheral RCH). Among the eyes with juxtapapillary RCH, tumor regression with partial resolution of macular edema was noted in two eyes (one eye each with half-fluence and full-fluence PDT), whereas two eyes had no change in tumor size with persistent macular edema. VA remained stable in three eyes and declined in one eye. In an eye with peripheral RCH, regression of tumor and macular edema with VA improvement was noted. Post-PDT complications included epiretinal membrane (one eye) and transient exudative retinal detachment (one eye).
  
  
  CONCLUSIONS
  PDT can be effective in reducing macular edema associated with RCH but this does not always correspond with an improvement in VA especially for juxtapapillary tumors.
authors.affiliation: Ocular Oncology Service, Moorfields Eye Hospital, London, UK.
authors.forename: V P
authors.initials: VP
authors.lastname: Papastefanou
authors.forename: S
authors.initials: S
authors.lastname: Pilli
authors.forename: A
authors.initials: A
authors.lastname: Stinghe
authors.forename: A J
authors.initials: AJ
authors.lastname: Lotery
authors.forename: V M L
authors.initials: VM
authors.lastname: Cohen
mesh_terms: D000328:Adult; D005260:Female; D018324:Hemangioma, Capillary / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult; D006623:von Hippel-Lindau Disease / Q000150:complications
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin